T. Fukuda et al., CYCLOSPORINE-A REDUCES T-LYMPHOCYTE ACTIVITY AND IMPROVES AIRWAY HYPERRESPONSIVENESS IN CORTICOSTEROID-DEPENDENT CHRONIC SEVERE ASTHMA, Annals of allergy, asthma, & immunology, 75(1), 1995, pp. 65-72
Background: Although cyclosporine A is proving effective for chronic s
evere asthma, its mechanism of action in this disease is unclear. Obje
ctive: This open study was conducted to determine whether cyclosporine
A therapy would reduce the degree of airway hyperresponsiveness and T
Iymphocyte activity. Methods: After a 6-week run-in period, nine pati
ents with corticosteroid-dependent chronic severe asthma were treated
with cyclosporine A (initial dose 5 mg/kg per day) for 12 weeks. Resul
ts: Weekly mean morning peak expiratory flow significantly increased i
n six subjects during the last 6 weeks of trial. Geographic mean PC20-
acetylcholine (the provocative concentration of acetylcholine required
to cause a 20% fall in FEV(1)) was 0.147 mg/mL before cyclosporine A
treatment and increased to 0.216 mg/mL at 6 weeks and to 0.379 mg/mL a
t 12 weeks after treatment. The increase at 12 weeks was statistically
significant (P < .05). The percentage of CD4-positive T lymphocytes b
earing IL-2 receptor (a marker of T cell activation) in the peripheral
blood decreased significantly at 6 weeks (P < .05), but returned to b
aseline value at 12 weeks, probably due to cyclosporine A dose reducti
on in seven subjects. Serum IgE levels and peripheral blood eosinophil
counts, however, which are dependent on IL-4 and IL-5, respectively,
were still significantly decreased at 12 weeks, suggesting lymphokine
production remained suppressed even after cyclosporine A dose was redu
ced. Conclusion: Taken together, these data suggest that cyclosporine
A may act in asthma, at least in part, by inhibition of T lymphocyte a
ctivation and by reducing the degree of airway hyperresponsiveness.